Heterogeneous Treatment Effect of Immune Checkpoint inhibitors by Pre-treatment Prognosis in Randomised Controlled Trials
The risk-modelling approach showed no clear link between pre-treatment prognosis and ICI efficacy in most RCTs, particularly those supporting atezolizumab's FDA label. In IMvigor211, patients with better pre-treatment prognosis were more likely to benefit from atezolizumab treatment for platinum-refractory metastatic urothelial carcinoma.
Authors
- Richard John Woodman (ORCID: https://orcid.org/0000-0002-4094-1222)
- Ganessan Kichenadasse (ORCID: https://orcid.org/0000-0001-9923-5149)
- Lee X. Li (ORCID: https://orcid.org/0000-0001-5259-5198)
- Natansh D. Modi (ORCID: https://orcid.org/0000-0003-3262-5374)
- Ashley M. Hopkins (ORCID: https://orcid.org/0000-0001-7652-4378)
- Ahmad Y. Abuhelwa (ORCID: https://orcid.org/0000-0002-4182-065X)
- Andrew Rowland
- Adel Shahnam
- Lewis Murray
Institutions
- Royal Adelaide Hospital (AU)
- Flinders University (AU)
- University of South Australia (AU)
- Peter MacCallum Cancer Centre (AU)
- Flinders Medical Centre (AU)
- University of Sharjah (AE)
- SA Health (AU)
- Adelaide Institute for Sleep Health (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1093/jncics/pkaf127
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00